EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Hipofosfatasia: perspectiva preclínica de su fisiopatología y tratamiento

José Luis Millán

EndoAr · 10.03.2026 · 2 (1) · 52-68

DOI: 10.65640/r60hpq49 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EndoAr, online erschienen am 10.03.2026. Verfasst von José Luis Millán. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypophosphatasia (HPP) is a genetic disorder caused by loss-of-function mutations in the ALPL gene, which encodes tissue-nonspecific alkaline phosphatase (TNAP), an enzyme essential for physiological skeletal and dental mineralization. Disease severity ranges from life-threatening perinatal and infantile forms to milder late-onset forms manifesting in adulthood or affecting only dentition. Enzyme replacement therapy based on recombinant mineral-targeted alkaline phosphatase (asfotase alfa) has been approved for the treatment of pediatric-onset HPP and has significantly improved survival and skeletal outcomes. This narrative review summarizes the pathophysiology of hypophosphatasia and discusses advances in preclinical research, including gene therapy approaches, small-molecule inhibitors, and cell-based therapeutic strategies evaluated in experimental models.

Zitieren

APA

Millán, J. L. (2026). Hipofosfatasia: perspectiva preclínica de su fisiopatología y tratamiento. EndoAr, 2(1), 52-68. https://doi.org/10.65640/r60hpq49

Vancouver

Millán JL. Hipofosfatasia: perspectiva preclínica de su fisiopatología y tratamiento. EndoAr. 2026;2(1):52-68. doi:10.65640/r60hpq49

BibTeX
@article{Milln2026,
  author = {Millán, José Luis},
  title = {Hipofosfatasia: perspectiva preclínica de su fisiopatología y tratamiento},
  journal = {EndoAr},
  year = {2026},
  volume = {2},
  number = {1},
  pages = {52--68},
  doi = {10.65640/r60hpq49}
}
Kostenlos starten →